Arcutis Biotherapeutics Inc ARQT

NAS: ARQT | ISIN: US03969K1088 19:36

10,09 USD (-0,05%)

(-0,05%) 19:36

Grafiek Arcutis Biotherapeutics Inc

Grafiek Arcutis Biotherapeutics Inc

1 dag1d -0,05%
1 week1w -19,26%
1 maand1m -1,47%
3 maanden3m 190,63%
6 maanden6m 168,58%
1 jaar1j -27,86%
5 jaar5j -53,74%

Arcutis Biotherapeutics Inc in het nieuws

Toon enkel gratis nieuws

1 december 2022 · MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis · Persbericht

8 september 2022 · LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million · Persbericht

30 augustus 2022 · New Campaign From Arcutis Aims To Expose The Impact Of Psoriasis On Physical, Mental, And Emotional Wellbeing · Persbericht

18 maart 2021 · Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo · Persbericht

17 maart 2021 · Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021 · Persbericht

25 februari 2021 · Arcutis to Present at the Cowen 41st Annual Health Care Conference · Persbericht

3 februari 2021 · Arcutis Biotherapeutics Announces Pricing of Upsized Public Offering of Common Stock · Persbericht

1 februari 2021 · Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock · Persbericht

1 februari 2021 · Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 Trials of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis · Persbericht

20 januari 2021 · Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis · Persbericht

Profiel Arcutis Biotherapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 269

Aandelen Arcutis Biotherapeutics Inc

Beurswaarde: 976,85 miljoen USD

Effecten: 96,81 miljoen

Winst per aandeel (12 maand): PLUS

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe